A “protective” effect of HIV-1 Env-specific IgG antibodies that activate NK cells has been demonstrated in ex vivo experiments (116) and in the RV144 HIV-1 vaccine trial, which demonstrated that the production of such antibodies was the strongest correlate of protection from the acquisition of HIV-1 infection (117). The gene discussed is ERVW-1; the disease is HIV-1 infection.